Cargando…

Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study

BACKGROUND: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Travis M., Rivera Mindt, Monica, Cunningham, Chinazo O., Arias, Franchesca, Coulehan, Kelly, Mangalonzo, Aprille, Olsen, Pat, Arnsten, Julia H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688712/ https://www.ncbi.nlm.nih.gov/pubmed/29141650 http://dx.doi.org/10.1186/s13011-017-0133-2

Ejemplares similares

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
por: Scott, Travis M., et al.
Publicado: (2021)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Sociodemographic and clinical characteristics of patients with long-term remission with buprenorphine / naloxone in opiate use disorder
por: Kahya, Y., et al.
Publicado: (2021)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058
por: Shava, Emily, et al.
Publicado: (2018)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
por: Martin, Yvette N., et al.
Publicado: (2019)

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
por: Ghosh, Abhishek, et al.
Publicado: (2022)

Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials
por: Bergen, Andrew W., et al.
Publicado: (2022)

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
por: Sadek, Joseph, et al.
Publicado: (2022)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder
por: Fox, Aaron D, et al.
Publicado: (2015)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
por: Bestepe, Engin Emrem, et al.
Publicado: (2020)

Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon
por: Ghaddar, Ali, et al.
Publicado: (2017)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
por: Regenstreif, Lori, et al.
Publicado: (2022)

Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
por: Kline, Anna, et al.
Publicado: (2023)

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder
por: Wipper, Benjamin, et al.
Publicado: (2023)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
por: Simojoki, Kaarlo, et al.
Publicado: (2008)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014)

Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
por: Lander, Laura, et al.
Publicado: (2017)

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy
por: Mattoo, Surendra K., et al.
Publicado: (2020)

Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022)

Character pathology and neuropsychological test performance in remitted opiate dependence
por: Prosser, James M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_62h20hhe0u7rr2oqpj48dvhnau